The Lautenberg Center for General and Tumor Immunology is a world-class research and teaching facility dedicated to eradicating a host of virulent diseases--cancer foremost among them.
At the Lautenberg Center, researchers investigate key aspects of cellular, biochemical and molecular immunology. Their diverse pioneering initiatives have applications for a range of devastating illnesses including cancer, Parkinson's disease, AIDS, multiple sclerosis, diabetes and rheumatoid arthritis. Lautenberg Center researchers maintain important international partnerships with laboratories around the world, joining with global community in the collective goal of developing effective treatments for life-threatening diseases.
Recent developments:
•
Conducting the research that led to the development of Gleevec, a revolutionary new drug for drug for chronic myelogenous leukemia
•
Inducing and maintaining a tumor-dormant state in breast and prostate carcinomas
•
Developing an innovative form of drug delivery that relays therapeutic agents directly to targeted immune system cells
•
Targeting colon cancer cells with p53 activators, a tumor suppressing protein
